TY - JOUR
T1 - International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers
AU - Amar, Laurence
AU - Pacak, Karel
AU - Steichen, Olivier
AU - Akker, Scott A.
AU - Aylwin, Simon J.B.
AU - Baudin, Eric
AU - Buffet, Alexandre
AU - Burnichon, Nelly
AU - Clifton-Bligh, Roderick J.
AU - Dahia, Patricia L.M.
AU - Fassnacht, Martin
AU - Grossman, Ashley B.
AU - Herman, Philippe
AU - Hicks, Rodney J.
AU - Januszewicz, Andrzej
AU - Jimenez, Camilo
AU - Kunst, Henricus P.M.
AU - Lewis, Dylan
AU - Mannelli, Massimo
AU - Naruse, Mitsuhide
AU - Robledo, Mercedes
AU - Taïeb, David
AU - Taylor, David R.
AU - Timmers, Henri J.L.M.
AU - Treglia, Giorgio
AU - Tufton, Nicola
AU - Young, William F.
AU - Lenders, Jacques W.M.
AU - Gimenez-Roqueplo, Anne Paule
AU - Lussey-Lepoutre, Charlotte
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/7
Y1 - 2021/7
N2 - Approximately 20% of patients diagnosed with a phaeochromocytoma or paraganglioma carry a germline mutation in one of the succinate dehydrogenase (SDHx) genes (SDHA, SDHB, SDHC and SDHD), which encode the four subunits of the SDH enzyme. When a pathogenic SDHx mutation is identified in an affected patient, genetic counselling is proposed for first-degree relatives. Optimal initial evaluation and follow-up of people who are asymptomatic but might carry SDHx mutations have not yet been agreed. Thus, we established an international consensus algorithm of clinical, biochemical and imaging screening at diagnosis and during surveillance for both adults and children. An international panel of 29 experts from 12 countries was assembled, and the Delphi method was used to reach a consensus on 41 statements. This Consensus Statement covers a range of topics, including age of first genetic testing, appropriate biochemical and imaging tests for initial tumour screening and follow-up, screening for rare SDHx-related tumours and management of elderly people who have an SDHx mutation. This Consensus Statement focuses on the management of asymptomatic SDHx mutation carriers and provides clinicians with much-needed guidance. The standardization of practice will enable prospective studies in the near future.
AB - Approximately 20% of patients diagnosed with a phaeochromocytoma or paraganglioma carry a germline mutation in one of the succinate dehydrogenase (SDHx) genes (SDHA, SDHB, SDHC and SDHD), which encode the four subunits of the SDH enzyme. When a pathogenic SDHx mutation is identified in an affected patient, genetic counselling is proposed for first-degree relatives. Optimal initial evaluation and follow-up of people who are asymptomatic but might carry SDHx mutations have not yet been agreed. Thus, we established an international consensus algorithm of clinical, biochemical and imaging screening at diagnosis and during surveillance for both adults and children. An international panel of 29 experts from 12 countries was assembled, and the Delphi method was used to reach a consensus on 41 statements. This Consensus Statement covers a range of topics, including age of first genetic testing, appropriate biochemical and imaging tests for initial tumour screening and follow-up, screening for rare SDHx-related tumours and management of elderly people who have an SDHx mutation. This Consensus Statement focuses on the management of asymptomatic SDHx mutation carriers and provides clinicians with much-needed guidance. The standardization of practice will enable prospective studies in the near future.
UR - http://www.scopus.com/inward/record.url?scp=85106446924&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106446924&partnerID=8YFLogxK
U2 - 10.1038/s41574-021-00492-3
DO - 10.1038/s41574-021-00492-3
M3 - Review article
C2 - 34021277
AN - SCOPUS:85106446924
SN - 1759-5029
VL - 17
SP - 435
EP - 444
JO - Nature Reviews Endocrinology
JF - Nature Reviews Endocrinology
IS - 7
ER -